Clinical trial
Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
NCT00044304 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Recruiting
Key facts
| NCT number | NCT00044304 |
|---|---|
| Title | Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome |
| Official title | Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients With Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Eosinophilic Myeloid Neoplasm, Hypereosinophilic Syndrome |
| Intervention type | Drug |
| Interventions | Imatinib, Ruxolitinib |
| Enrollment | 80 |
| Start date | Sep 26, 2002 |
| Primary completion | Mar 10, 2026 |
| Completion | Mar 10, 2026 |
| First posted | Aug 26, 2002 |
| Last update posted | Jan 23, 2026 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: